Biocause Pharma(SZ:000627) 中国基金报·2025-09-05 00:26Core Viewpoint - *ST Tianmao plans to voluntarily delist from the Shenzhen Stock Exchange due to difficulties in disclosing its annual report, aiming to protect shareholder interests through a resolution at the shareholders' meeting [2][4]. Group 1: Delisting Process - On August 8, *ST Tianmao first announced its intention to voluntarily delist its A-shares from the Shenzhen Stock Exchange [4]. - The company received approval for the delisting at its 2025 first extraordinary shareholders' meeting held on August 25, and subsequently submitted the delisting application to the exchange [4]. - After delisting, *ST Tianmao intends to maintain stable operations and protect shareholder rights, with no current plans for major asset restructuring or a timeline for potential relisting [4]. Group 2: Financial Reporting Issues - *ST Tianmao was unable to disclose its 2024 annual report and the 2025 first-quarter report within the legal timeframe, leading to a delisting risk warning on July 8, 2025 [6]. - If the company fails to disclose a majority of its board's assurance of the report's authenticity within two months of the delisting risk warning, the Shenzhen Stock Exchange will decide to terminate its stock listing [6]. Group 3: Regulatory Actions - On May 6, *ST Tianmao received a notice from the China Securities Regulatory Commission regarding an investigation for failing to disclose periodic reports on time [7]. Group 4: Company Background - *ST Tianmao was publicly listed in 1996 and underwent a significant ownership change in 2002 when Liu Yiqian became the actual controller after acquiring the company [8]. - The company transitioned from a pharmaceutical focus to insurance, primarily operating through its subsidiaries, Guohua Life and Huarui Insurance [8]. - As of August 13, the company's stock price was 1.58 yuan per share, with a total market capitalization of 7.7 billion yuan, and it had over 110,000 shareholders as of July 18 [8][10].